EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Replimune Group Inc (REPL) fair value: what the stock is really worth

As of Oct 15, 2026: fair value of Replimune Group Inc $1.20, price $11.75, upside -89.8%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

RG Replimune Group Inc logo Thin data Oct 16, 2026

Replimune Group Inc

REPL · US

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 90% below what the stock costs today.

Moderate debt
Fair value $1.20 · Strongly overvalued (−89.8%)
Quality 33/100
Negative free cash flow
Trails peers (2/8)
Narrow moat 6/100 · thin data
Thin data
Watch Replimune Group Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$36.33 $1.70 Fair Value $1.20 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 16, 2026.

How to read this chart

60‑month range $1.70 – $36.33 · fair‑value band $0.7900 – $1.50 · the $11.75 price screens above the $1.20 fair value. Dashed = 300-day average. As of Oct 16, 2026.

Follow Replimune Group in your weekly email

Every Wednesday you see whether Replimune Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Show moreShow less

Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.

The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells.

Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Stock analysis

Replimune Group Inc (REPL) currently trades at $11.75, while our model-based Fair Value estimate is $1.20, 89.8% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.7900 (bear) to $1.50 (bull), the price of $11.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Replimune Group Inc reported revenue of $0 in FY2026 versus $0 in FY2022. Reported net income was −$314M in FY2026.

Key figures

Market cap $1.1B · EPS (TTM) $−3.15 · Return on equity −134% · Return on assets (EBIT) −49.1% · Free cash flow −$285M · Net cash $97.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 591% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −90%, REPL screens richer than that median.

Fair Value models

Bear $0.7900 Fair Value $1.20 Bull $1.50
Price $11.75 · Upside -89.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.8800 $1.18 $1.76 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.8800 $1.18 $1.76 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Momentum 90
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 85
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

REPL screens overvalued: fair value 90% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Replimune Group Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 603 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −89.8% · Bottom 25%
Profitability
Return on assets −94.5% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth 0.0% · Above median
Balance sheet
Debt / equity 0.50× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.85× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)75 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $746.54 $1,275 +71% vs REPL
Vertex Pharmaceuticals Incorporated VRTX $510.08 $561.09 +10% vs REPL
argenx SE ARGX $825.03 $907.53 +10% vs REPL
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs REPL
WuXi Biologics (Cayman) Inc 2269 HK$52.65 HK$57.92 +10% vs REPL
CSL Limited CSL A$181.46 A$179.90 −1% vs REPL
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs REPL
BeOne Medicines AG ONC $354.47 $280.94 −21% vs REPL
Celltrion, Inc 068270 180,400 KRW 74,519 KRW −59% vs REPL
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs REPL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Replimune Group Inc · Fair Value
$1.20 −90%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Replimune Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/REPL.US

Frequently asked questions

Is Replimune Group Inc (REPL) overvalued or undervalued?
As of Oct 16, 2026, our model estimates a fair value of $1.20 versus a price of $11.75, about −90% upside (overvalued).
What is the fair value of REPL?
Our model-based fair value for Replimune Group Inc is $1.20 (as of Oct 16, 2026), built from audited fundamentals. The current price: $11.75.
What is the quality score of REPL?
Replimune Group Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Replimune Group Inc (REPL)?
Our model-based price target is the fair value of $1.20 (as of Oct 16, 2026) from 1 valuation models. Cautious scenario $0.7900, optimistic scenario $1.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Replimune Group Inc stock forecast for 2026?
Our models put fair value at $1.20, about −90% upside versus a price of $11.75 (overvalued). Cautious scenario $0.7900, optimistic scenario $1.50. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Replimune Group Inc (REPL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Replimune Group Inc it is $1.20 per share (as of Oct 16, 2026), against a price of $11.75. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Replimune Group Inc stock overvalued or undervalued in 2026?
As of Oct 16, 2026, REPL trades above its calculated fair value: price $11.75, fair value $1.20, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of REPL?
No. The price is what the market pays today ($11.75); the fair value is what the company's own numbers justify ($1.20). For Replimune Group Inc the two are $10.55 per share apart. That gap is exactly why we show both numbers side by side.
How much is Replimune Group Inc worth?
The market values Replimune Group Inc at about $1.1B (market capitalisation, as of Oct 16, 2026). Per share that is $11.75; our models calculate a fair value of $1.20 per share.
What do the bullish and bearish scenarios say about REPL?
Our models span a range for Replimune Group Inc: cautious scenario $0.7900, base $1.20, optimistic $1.50 per share (as of Oct 16, 2026, price $11.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Replimune Group Inc (REPL)?
Balance-sheet figures for Replimune Group Inc (as of Oct 16, 2026): return on equity −134.3%, debt of 0.50 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is REPL from its 52-week high?
Replimune Group Inc trades at $11.75, about 26% below its 52-week high of $15.98 and 591% above the low of $1.70 (as of Oct 15, 2026). Distance from the high says nothing about value: that is what the fair value of $1.20 is for.
Which stocks are comparable to Replimune Group Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Replimune Group Inc stock attractive at the current price?
The data as of Oct 16, 2026: price $11.75, calculated fair value $1.20 (−90%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of REPL calculated?
We run Replimune Group Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.20, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Replimune Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Replimune Group Inc (REPL)?
The closing price on Oct 15, 2026 was $11.75. Our model-based fair value is $1.20, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Replimune Group Inc right now?
The price sits above even our optimistic bull case ($1.50). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.7900 to $1.50) leaves room in how you read the outcome.

Key figures of Replimune Group Inc

How large is the market capitalisation of Replimune Group Inc (REPL)?
The market capitalisation of Replimune Group Inc is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Replimune Group Inc (REPL)?
Earnings per share at Replimune Group Inc are $−3.15. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Replimune Group Inc (REPL)?
The return on equity (ROE) of Replimune Group Inc is −134% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Replimune Group Inc (REPL)?
On an EBIT basis the return on assets of Replimune Group Inc is −49.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Replimune Group Inc (REPL) generate?
The free cash flow of Replimune Group Inc is −$285M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Replimune Group Inc (REPL) hold?
Replimune Group Inc holds more cash than debt, $97.4M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Replimune Group Inc in the live analysis

One click puts Replimune Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.